Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials

OASIS 5 and 6 Investigators, Shamir R Mehta, William E Boden, John W Eikelboom, Marcus Flather, P Gabriel Steg, Alvaro Avezum, Rizwan Afzal, Leopoldo S Piegas, David P Faxon, Petr Widimsky, Andrzej Budaj, Susan Chrolavicius, Hans-Jurgen Rupprecht, Sanjit Jolly, Christopher B Granger, Keith A A Fox, Jean-Pierre Bassand, Salim Yusuf

Research output: Contribution to journalArticlepeer-review

Abstract

The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST- and ST-segment elevation acute coronary syndromes, respectively. Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported.
Original languageEnglish
Pages (from-to)2038-46
Number of pages9
JournalCirculation
Volume118
Issue number20
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Dive into the research topics of 'Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials'. Together they form a unique fingerprint.

Cite this